Stemedica Cell Technologies, manufacturer of adult

Stemedica is a world premier developer, manufacturer and distributor of allogeneic adult stem cell technology

[stemcelltechnologies-blog-blog]

Stemedica Announces the Appointment of Dr. César Amescua Garcia as Medical and Regulatory Affairs Director – Latin America

Stemedica Cell Technologies, Inc., a leader in allogeneic adult stem cell manufacturing, research and development announced today the appointment of César Amescua, MD as Medical and Regulatory Affairs Director for Latin America.  Dr. Amescua will be responsible for liaison with regulatory agencies in Latin America regarding approvals of Stemedica’s stem cell products for use in clinical (human) trials which follow the criteria required by the FDA in the United States.   

Dr Amescua is a member of the senior medical leadership at Groupo Angeles, one of the largest health care providers in all of Latin America. He is also President of the Mexican Association for the Study and Treatment of Pain.  “I am excited and proud to be working with Stemedica. The company is a leader in the stem cell manufacturing field, and is bringing innovative technology to countries around the world.  Latin America holds great promise for Stemedica’s products and services as Latin America seeks to address the epidemic of degenerative diseases and conditions that are bankrupting health care systems around the world.” 

Dr. Lev Verkh, Stemedica’s Chief Regulatory and Clinical Development Officer, commented, “We’re pleased and delighted to have Dr Amescua joining our team at Stemedica.  His medical leadership and his regulatory expertise will be critical in establishing clinical trials throughout Latin America using Stemedica stem cell products.” 

“With the rapid advancement of the clinical application and development of adult stem cell therapy around the world, the addition of Dr. Amescua’s medical leadership and regulatory expertise is critical in establishing extensive clinical trials for our products,” said Dr. Nikolai Tankovich, Stemedica’s President and Chief Medical Officer.  

[stemcelltechnologies-blog-blog]

Stemedica is a biopharmaceutical company that develops and manufactures adult stem cell products for use in clinical and pre-clinical trials. Currently within the USA the research activities are pre-clinical. Internationally we have clinical and pre-clinical studies

[stemcelltechnologies-blog-blog]

Dr. Maynard Howe, CEO of Stemedica, the Leading Allogeneic Adult Stem Cell Manufacturer, Joins USO Board of Governors

Dr. Maynard A. Howe, CEO and Vice Chairman of Stemedica Cell Technologies Inc. (“Stemedica”), an allogeneic adult stem cell manufacturer, was welcomed as the newest member of the USO Board of Governors during their May Board Meeting held in San Antonio, Texas. Dr. Howe brings a richly diverse background to the USO as Chairman, CEO, COO, CTO, and Executive Vice President of Marketing and Sales of many organizations, while serving as a consultant to more than fifty Fortune 500 companies worldwide.

  “We are excited to bring Maynard on board with the USO,” said Edward Reilly, Chairman of the USO Board of Governors. “His leadership, research and consulting experience will be a special asset to the USO as we expand our services to U.S. troops and their families.”

  Along with his brother, Roger, Dr. Howe launched five successful ventures in the medical device, software, testing and measurement, quality and consulting fields, including Stemedica. Stemedica is the world's leading developer, manufacturer and distributor of allogeneic adult stem cell technology. Stemedica recently received an IND approval from the FDA to initiate stem cell clinical research trials in the United States for ischemic stroke using allogeneic adult stem cells. and outside of the United States for several other neurological trials.

  “I’m honored and delighted to be a member of the USO Board of Governors,” said Dr. Howe. “I have always had a deep passion for supporting our dedicated soldiers.  Joining the USO Board of Governors allows me to combine my passion, diverse contact base and medical knowledge in service to our troops.” 

  Dr. Howe is a sought after facilitator, lecturer and speaker. He holds a Bachelor of Science Degree in Business Management, Master of Science Degree in Educational and Counseling Psychology and a Doctorate in Clinical Psychology.  He is the author and co-author of numerous articles and top selling business books. His book on quality, Quality on Trial, Bringing Customer Relationships into Focus, is in its second edition and has been published in several languages. Other books include a five-part implementation manual series, Business-to-Business Marketing Management System, published by McGraw-Hill.

[stemcelltechnologies-blog-blog]

The Allogeneic Adult Stem Cells Company Announcing Appointment of Dr. Lev Verkh

Lev Verkh is now a part of Stemedica, the allogeneic adult stem cells manufacturing company for effective stem cell clinical trials, thus improving the life of humans.

The allogeneic adult stem cells manufacturer, Stemedica Cell Technologies, Inc., (a leader in adult stem cell research as well as manufacturing), announced today the appointment of Lev Verkh, PhD as Chief Regulatory and Clinical Development Officer.  Dr. Verkh will be responsible for managing all regulatory activities and clinical trials on behalf of this allogeneic adult stem cells manufacturing company. . “Dr. Verkh brings over twenty years of international regulatory and clinical trial experience to Stemedica,” said Dr. Nikolai Tankovich, Stemedica’s President & Chief Medical Officer.  “We are confident that his contribution to our mission to bring innovative products to patients, following FDA guidelines, will be significant.” 

  Dr. Verkh’s clinical and regulatory experience includes working for Pfizer, Baxter Bio Sciences, the Alliance Pharmaceutical Corporation and the Alpha Therapeutic Corporation. He has directed national and multi-national Phase I, II, III and IV clinical trials in such areas as cardiology, oncology, peripheral artery disease, hematology, blood disorders and imaging methods.  He is author or co-author of over 40 peer-reviewed publications.  Through his efforts and the efforts of his teams, he has received FDA approval for several products that are currently on the market.  “I am honored to be joining Stemedica’s management team,” said Dr. Verkh, “and am excited to work with the company’s leading-edge allogenic adult stem cells technology.”

  In addition to directing Stemedica’s stem cell clinical trials within the United States, Dr. Verkh will be assisting foreign regulatory agencies to establish guidelines for this allogeneic adult stem cells manufacturing unit in medicine.  He will also assist in organizing and supervising stem cell clinical trials outside the United States utilizing Stemedica technology.

  “With the rapid advancement of clinical application and development of allogeneic adult stem cells technologies around the world, the addition of Dr. Verkh is essential to our long-term growth plan”, said Maynard Howe, PhD, Stemedica’s Chief Executive Officer.  “Stemedica is working closely with government leaders, scientists and clinicians to establish and promote best scientific practices in the emerging field of stem cell research and therapy.”  The allogenic adult stem cells manufacturing company is preparing to improve medical condition of every human being to the maximum level.

[stemcelltechnologies-blog-blog]

Stemedica Cell Technologies, manufacturer of adult stem cells.

Stemedica’s core mission is to develop, manufacture and distribute allogeneic adult stem cells that have the potential to save, restore and improve lives by reversing the debilitating nature of complex diseases or physical trauma. This mission is central to everything the Company does, and Stemedica management and employees are dedicated to executing this mission with great passion and with business and scientific discipline. Stemedica has a deep appreciation for the impact its scientific and medical technologies have on the lives of patients, their families, and friends and is pursuing stem cell clinical trials to widen the opportunities for stem cell treatment. There is a sense of pride, belonging, and purpose about being the world's leading stem cell manufacturing company that permeates every aspect of the Company’s endeavors. Stemedica’s founders, directors, scientists, doctors, and staff are united in this mission to be the foremost clinical grade stem cell manufacturer. The Company’s dedicated approach to stem cell research in medicine, mesenchymal stem cell in science, and the business of stem cell clinical research trials is reflected in the quality-control around stem cell therapy, license to manufacture clinical grade stem cells, care with respect to human stem cells, thoughtfulness in dealing with stem cell technologies and professionalism as a stem cell manufacturer with which the Company pursues every aspect of its clinical grade operations. Maynard Howe, CEO of Stemedica Cell Technologies, is supported by Alex Kharazi and Nikolai Tankovich in delivering neuronal stem cells in support of adult stem cell treatment.